Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Core Laboratories Inc. /DE/ (CLB)

Core Laboratories director Kwaku Temeng to resign effective October 1, 2026

Neutral Impact 3 of 5 leadership Written later

Core Laboratories director Kwaku Temeng confirmed in an August 25, 2026 letter that he will resign from the Board effective October 1, 2026. He chairs the Nominating Committee and sits on the Compensation Committee, and his letter cites a disagreement with the Board over strategic direction and certain governance practices.

Key points

  • Kwaku Temeng first notified the Board verbally on August 19, 2026, and confirmed his resignation by letter on August 25, 2026.
  • Resignation is effective October 1, 2026; he serves as Chairman of the Nominating Committee and as a member of the Compensation Committee.
  • The Board says the main disagreement involves how the Company handles succession planning, a process a majority of directors supports; the Board also says he has concerns about research priorities.
  • Temeng has served on the Board for more than five years; his resignation letter is filed as Exhibit 17.1.

The filing

CompanyCore Laboratories Inc. /DE/ (CLB)
Form8-K, current report
Filed with the SECAug 25, 2026, 4:51 PM ET
Accession number0001193125-26-365271

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 25, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.